“…Organoid and organ-on-a-chip technologies are suitable replacement for animal models and will potentially impart multicellular in vitro organoid-related information on mechanisms of human toxicity and disease etiology. Organoids have been made from primary cell cultures, differentiated embryonic stem cells, or differentiated induced pluripotent stem cells (iPSC) for the liver (Cao et al, 2017 ), the heart (Beauchamp et al, 2015 ; Conant et al, 2017 ; Devarasetty et al, 2017 ), the brain (Hunsberger et al, 2015 ; Schwartz et al, 2015 ), the kidney (Astashkina et al, 2012 ; Chuah and Zink, 2017 ), the testes (Baert et al, 2017 ), the bladder (Janssen et al, 2013 ), and potentially multiple other organs and tissues (Xinaris et al, 2015 ; Ingersoll et al, 2016 ; Skardal et al, 2016 ). Liver toxicity, indicated by liver cell death (Weber et al, 2016 ; Wong et al, 2016 ), and cardiac toxicity, indicated by changes in heart beat kinetics (Meattini et al, 2017 ; Yu et al, 2017 ), account for most drug candidate failures in human trials.…”